期刊文献+

美国药品安全法律责任设置的特点及其对我国的启示 被引量:4

Characteristics of Legal Liability Setting for Drug Safety in the United States and Its Enlightenment for China
下载PDF
导出
摘要 目的:为完善我国药品安全法律责任设置提供借鉴。方法:采用文献研究的分析方法,全面梳理美国在药物临床研究、上市申请、生产、销售、广告、上市后监测、召回等环节设置的法律责任(包括行政责任和刑事责任)的特点,并据此对我国药品安全相关法律责任的设置提出建议。结果与结论:美国药品安全法律责任具有责任设置明确合理、惩罚机制严厉、行政制裁措施灵活高效、通过激励机制鼓励诚信自律等特点。我国应立足国内实际,充分借鉴美国药品立法方面的先进经验,通过加大对违法犯罪行为的惩罚力度、进一步完善行刑衔接机制、细化违法药品分类及法律责任划分、建立合理的激励机制等手段进一步完善我国药品安全法律责任设置,提高我国药品安全监管水平,实现保障公众健康和用药安全的目标。 OBJECTIVE:To provide reference for perfecting the legal liability setting for drug safety in China. METHODS:By literature study analysis,the characteristics of legal liability in the United States were reviewed comprehensively in respects of drug clinical research,listing application,production,marketing,advertising,post-marketing surveillance,recall,etc. Based on this,some suggestions were put forward for setting up the legal liability for drug safety in China. RESULTS CONCLUSIONS:The liability setting for drug safety in the United States has the following characteristics as clear and reasonable liability,strict punishment mechanism,flexible and efficient administrative sanctions,and incentive mechanism of encouraging honesty and self-discipline. Our country should learn from the advanced experience of drug legislation in the United States based on domestic practice. It is necessary to increase penalties for illegal activities,further improve the cohesion mechanism of administrative law enforcement and criminal justice,specify categories of illegal drugs and the legal liability,and establish a reasonable incentive mechanism,in order to improve drug safety legal liability setting,strengthen drug safety regulation and achieve the goal of ensuring public health and drug safety.
作者 刘志强 杨悦 LIU Zhiqiang;YANG Yue(School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China;Free Trade Zone Branch,Ningbo Municipal Bureau of Market Supervision and Administration,Zhejiang Ningbo 315800,China)
出处 《中国药房》 CAS 北大核心 2018年第16期2161-2166,共6页 China Pharmacy
基金 国家食品药品监督管理总局药化注册司委托课题(No.20170012)
关键词 美国 药品安全 法律责任 行政 刑事 启示 The United States Drug safety Legal liability Administration Criminal Enlightenment
  • 相关文献

参考文献5

二级参考文献29

  • 1赵蓓,王准,宋民宪.药品警示缺陷概念分析[J].中药与临床,2013,4(2):56-58. 被引量:2
  • 2胡颖廉.沿海十省(市)药品监管机构能力之比较研究[J].公共管理学报,2007,4(1):97-103. 被引量:17
  • 3CHPA. A History of Self - Regulation [ EB / OL]. (2010 - 04 - 02). http : //www. ndmainfo, org/about/aboutFrame, html.
  • 4Steven A. Grossman. OTC Medications, Advertising and the Public Health: USA Perspective[EB/OL] . (2010 -04 - 10) . http://www, hpsgroup. com/hpshtml/writings/hpsOTCMedications2 - 16. pdf.
  • 5Francis B, Palumbo C, Daniel Mullins. The Development of Directto-Consumer Prescription Drug Advertising Regulation[J]. Food and Drug Law Journal, 2002, 57 (3) :423 - 443.
  • 6大众医药网.美国重罚四大减肥药虚假广告[EB/OL](2010-04-10).http://news.5lqe.cn/gjyy/62849.html.
  • 7FDA. Memorandum of Understanding Between The Federal Trade Commission and The Food and Drug Administration [EB/OL]. (2009-04-10). http : //www. fda. gov / AboutFDA / PartnershipsCollaborations / Memoranda of UnderstandingMOUs / DomesticMOUs / ucm 115791. htm.
  • 8FTC. Priorities for Dietary Supplement Advertising Enforcement[EB/OL]. (2009 - 04 - 10) . http : //www. ftc. gov/speeches/vladeck/091022vladeek crnspeech, pdf.
  • 9Minnesotamedicine. Direct- to- Consumer Prescription Drug Advertising History, Regulation, and Issues [EB/OL]. (2010 -04 - 10). http:// www. minnesotamedieine, com/Currentlssue/ClinicalJisuMarch2010/rabid / 3351/Default. aspx.
  • 10[美]史蒂芬·布雷耶.《打破恶性循环:政府如何有效规制风险》,宋华琳译,法律出版社2009年版,“译者的话”第lO页.

共引文献42

同被引文献39

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部